Navigation Links
Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians
Date:11/9/2011

MIAMI BEACH, Fla., Nov. 9, 2011 /PRNewswire/ -- Biotech developer Divine Skin Inc. (OTC Bulletin Board: DSKX) which has been expanding the topical hair-growth segment, is rolling out that market's newest, most potent, only customizable system, Polaris API Solution 9, to be supplied by physicians for treatment through multiple methods of action.

With well-established materials like minoxidil sulfate, finasteride, alfatradiol, and other active ingredients, Polaris API Solution 9 is the most complete solution that can be used for hair loss, either by prescription or over the counter configured to the individual needs of the patient by physicians. The current sales leader contains only 5% minoxidil in a standard carrier.

"We are launching a new category," declared CEO Daniel Khesin, speaking on a conference call with investors. "We expect this line to change the game and to offer a powerful new tool for dermatologists that can really make a difference in their approach to treatment."

Half of all men will experience some hair loss by age 50, and they can only purchase the customized Polaris product through physicians, who can create the potent mix of active pharmaceutical ingredients (API).

Divine Skin, which posted revenue of $5.4 million in 2010 — up 55 percent over the previous year — creates a major new revenue stream with Polaris API Solution 9, and stockholders expect to benefit for several years.

In published clinical trials, each major component of the new API — minoxidil sulfate, finasteride, and alfatradiol — has proven to inhibit androgenic alopecia (male pattern baldness) effectively. The system also includes other auxiliary agents like apple polyphenol, copper peptides, nutrients, and conditioners to enhance the formula further.

"With very few options available," says Khesin, "Polaris API Solution 9
'/>"/>

SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Divine Skin Posts Record Sales for 2010: Up 55% Over 2009
2. Divine Skin Announces Four Deals for Explosive Distribution Growth
3. First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin
4. Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX)
5. Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil
6. Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010
7. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
8. Rice rolls out new nanocars
9. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
10. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
11. Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
(Date:7/27/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Thursday, July 30, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... announced a new video: 3 Ways to GHS Labels . This video ... the Globally Harmonized System (GHS) by effectively labeling chemical containers. , “With the ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 /PRNewswire-USNewswire/ ... today announced the winners of its annual ... basic research by scientists who have been supported ... early career scientists to pursue innovative ideas in ... generate "proof" of concept for the early detection, ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Indian company to purchase, distribute US-made bulk ... Specialty chemicals,maker Albemarle Corporation (NYSE: ... anti-inflammatory agent ibuprofen and other active pharmaceutical,ingredients ... pharmaceutical,company Dr. Reddy,s Laboratories Ltd. As per ...
... ST. JOSEPH, Mich., July 8 GeneGo, Inc., ... Keck Microarray Center,at Yale has become a certified ... access to GeneGo,s MetaCore, training and advanced,support., ... (Keck Lab),one of the largest biotechnology laboratories of ...
... market and business intelligence company, the enzyme market is significant ... 6.5 to 10%. Enzymes are sold in many different industry segments. ... , ... Paris (PRWEB) July 8, 2008 -- According ...
Cached Biology Technology:Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 3
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... April 14, 2013) Through a collaborative genome-wide study ... that are associated with heart rate. Since heart ... could provide a better understanding of genetic regulation of ... targets for new drugs to treat cardiovascular disease. ...
... 14, 2013)Drug-eluting stents can keep clogged leg arteries ... being presented at the Society of Interventional Radiology,s ... "Peripheral arterial disease (or PAD) is becoming increasingly ... obesity and diabetes epidemics," said Robert A. Lookstein, ...
... Injury: Latest News on Clinical Trials of Interventions to ... 17, 2013, from 4:30 to 6:30 p.m., at Kessler ... special Grand Rounds is presented by the Northern New ... Cord Injury Project of the W. M. Keck Center ...
Cached Biology News:Mount Sinai study identifies new gene variations associated with heart rate 2Drug-coated stents prevent leg amputation 2The State of Spinal Cord Injury Grand Rounds 2
... at the 9, 10, 12, and 13 positions. ... standard for the quantification of 13(S)-HODE by GC- ... of linoleic acid with plant and mammalian lipoxygenases. ... of tumor cells to the endothelium at concentrations ...
...
...
...
Biology Products: